Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality of life measure for adult atopic dermatitis

Abstract

The Harmonizing Outcome Measures for Eczema (HOME) initiative identified quality of life (QoL) as a core outcome domain that should be assessed in all atopic dermatitis (AD) trials.¹ However, based on a systematic review of the measurement properties of QoL instruments, HOME could not reach consensus on which QoL instrument should be recommended for adult AD.^2,3 In response to the need for a valid QoL instrument, we developed the Burden of Disease in Atopic Eczema (BODE) instrument.

This article is protected by copyright. All rights reserved.